References^ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. avapro irbesartan "Renoprotective effect of the avapro irbesartan antagonist irbesartan in patients with nephropathy due to type 2 diabetes,[1] hypertension and microalbuminuria (>30 mg/24.

Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3 IrbesartanFrom Wikipedia, the avapro irbesartan encyclopedia(Redirected from Avapro)Jump to: navigation, searchIrbesartanSystematic (IUPAC) name2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-oneIdentifiersCAS number 138402-11-6ATC code C09CA04PubChem 3749DrugBank avapro irbesartan dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half life 11–15 hoursExcretion avapro irbesartan 20%, faecal 65%Therapeutic considerationsLicence avapro irbesartan EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists, irbesartan is indicated for the reduction avapro irbesartan renal disease progression in patients with nephropathy due to avapro irbesartan 2 diabetes.". N Engl J Med 345 (12): 851-60. PMID 11565517.^ Rossi S, editor. Australian.

article: Angiotensin II receptor antagonists, irbesartan is indicated for the treatment for.